ABSTRACT
Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. Here, we analyzed the brain transcriptomics data of more than 600 AD patients using genome-scale metabolic models and provided supporting evidence of mitochondrial dysfunction related to the pathophysiologic mechanisms of AD progression. Subsequently, we investigated, in a rat model of AD, the oral administration of Combined Metabolic Activators (CMA), consisting of NAD+ and glutathione precursors, to explore the effect for improvement of biological functions in AD. CMA includes L-serine, nicotinamide riboside, N-acetyl-L-cysteine, and L-carnitine tartrate, salt form of L-carnitine. The study revealed that supplementation of the CMA improved the AD-associated histological parameters in the animals. Finally, we designed a randomized, double-blinded, placebo-controlled human phase 2 clinical trial and showed that the administration of CMA improves cognitive functions in AD patients. As decreased AD Assessment Scale-cognitive subscale (ADAS-Cog) score is the indicator of the improved cognitive function in AD patients, we observed a significant decrease of ADAS-Cog scores on Day 84 vs Day 0 (Log2FC= -0.37, (29% improvement), p-value=0.00001) in the CMA group. We also observed a significant decrease in the placebo group on Day 84 vs Day 0 (Log2FC= -0.19, (14% improvement), p-value=0.001) due to the recommendations of exercise and Mediterranean diet to all AD patients participated in the trial. A comprehensive analysis of the human plasma metabolome and proteome revealed that plasma levels of proteins and metabolites associated with redox metabolism are significantly improved after treatment. In conclusion, our results show that treating AD patients with metabolic activators leads to enhanced cognitive functions, suggesting a role for such a therapeutic regime in treating AD and other neurodegenerative diseases.
HIGHLIGHTS
Brain transcriptomics data of more than 600 AD patients is analysed.
Performed an in vivo study using Combined Metabolic Activators (CMA) in AD rat models.
We performed a randomized, double-blinded, placebo-controlled human phase 2 clinical trial.
We showed that cognitive functions in AD patients is improved 29% in the CMA group whereas 14% in the placebo group.
Competing Interest Statement
AM, JB and MU are the founder and shareholders of ScandiBio Therapeutics. The other authors declare no competing interests.
Clinical Trial
NCT04044131
Funding Statement
This work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation. The authors would like to thank the Metabolon Inc. (Durham, USA) for generation of metabolomics data, and ChromaDex Inc. (Irvine, CA, USA) for providing NR. AM and HY acknowledge support from the PoLiMeR Innovative Training Network (Marie Sklodowska-Curie Grant Agreement No. 812616) which has received funding from the European Union's Horizon 2020 research and innovation programme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee approved the study of Istanbul Medipol University, Istanbul, Turkey, and retrospectively registered at https://clinicaltrials.gov/ with Clinical Trial ID: NCT04044131.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Lead author: Adil Mardinoglu (adilm{at}scilifelab.se)
Emails: burakyulug{at}gmail.com; havva.altay{at}scilifelab.se; xiangyu.li{at}scilifelab.se; lhanoglu{at}kure.com.tr; cankayaseyda{at}hotmail.com; simon.1.lam{at}kcl.ac.uk; hong.yang{at}scilifelab.se; ebrucosskun{at}gmail.com; ezgi.idil92{at}gmail.com; ngylrrhm{at}gmail.com; cemil489{at}gmail.com; ismail.bolat{at}atauni.edu.tr; senaoner02{at}gmail.com; ozlem.ozdemir{at}erzurum.edu.tr; enesiyte{at}gmail.com; ahmeth{at}atauni.edu.tr; syildirim{at}atauni.edu.tr; muhammad.arif{at}scilifelab.se; saeed.shoaie{at}scilifelab.se; cheng.zhang{at}scilifelab.se; nielsenj{at}chalmers.se; hasanturkez{at}yahoo.com; Jan.Boren{at}wlab.gu.se; mathias.uhlen{at}scilifelab.se; adilm{at}scilifelab.se
We added 1 citation (Yulug et al, 2021) We included percentages of ADAS-Cog scores throughout the manuscript.
Data Availability
All available data included in the supplementary datasets.
